The biotech iQure Pharma Inc. has announced that the analgesic compound iQ-008 demonstrated efficacy in in vivo experiments.
In particular, Wilmington, Delaware-based iQure announced that iQ-008 meets Lipinski’s rule of five criteria. Also known as Pfizer’s rule of five, the Rule of 5 (RO5) helps pharmaceutical companies determine whether a compound is druglike.
Additionally, iQure announced that the iQ-008 demonstrated significant effects in all pain models in preclinical efficacy screenings.
iQure is developing the drug as a potential treatment for neuropathic pain such as peripheral neuropathy, which affects approximately 20 million people in the U.S.
“This is very good news and an important step in the development of iQ-008 as a promising therapeutic,” said iQure CEO Pawel Zolnierczyk in a press release. “The results of efficacy after oral dosing are a further indication that iQ-008 will be viable in capsule or tablet form in human studies. We are encouraged for successful in vivo studies by the data confirming that iQ-008 meets the Lipinski/Pfizer Rule of Five,” he added.
Filed Under: Neurological Disease